LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA® in Chinese healthy male subjects

Background: This study aimed to investigate the pharmacokinetics, safety, and immunogenicity of recombinant humanized anti-human IL-6R monoclonal antibody injection, LZM008, and evaluate the pharmacokinetic similarity between LZM008 and tocilizumab (ACTEMRA®) in Chinese healthy male subjects.Researc...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Guoying Cao, Jingjing Wang, Jinjie He, Yingying Hu, Haijing Yang, Linling Que, Xianghong Gu, Jicheng Yu, Xiaojie Wu, Jufang Wu, Wei Fang, Qing He, Jing Zhang
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2023-04-01
Seri Bilgileri:	Frontiers in Pharmacology
Konular:	biosimilar tocilizumab pharmacokinetics immunogenicity safety
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1111893/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!